Loading…
← CockpitCompetitor Analysis › 000028.SZ China National Accord Medicines Corporation Ltd Class AOpen in the cockpit ↗

China National Accord Medicines Corporation Ltd Class A000028.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Sinopharm-group pharma distributor and manufacturer serving Guangdong and South China's hospitals and pharmacies.

≈ A regional McKesson with a small factory armMomentum leader 92
Mkt cap
$1.81B
US dollars, full cap
Free float
35%
of shares outstanding
$/day
$12.2M
20-day average traded
Fwd P/E
10.8×
forward earnings
ROIC−WACC
+1.4 pp
WACC 5.0%
Hurdle
-14 pp
Req g minus delivered
Next earnings
147 days
14 Apr 2027
Close · CNYCN¥21.24
1D+0.7%
1W+1.4%
1M+5.5%
3M+4.6%
6M-3.2%
YTD-4.9%
1Y-7.5%
ATR %2.0%
52w lowhigh14.8% off high

What China National Accord Medicines does

Sinopharm-group pharma distributor and manufacturer serving Guangdong and South China's hospitals and pharmacies.

Earns a small margin on each drug it buys from manufacturers and delivers to hospitals and pharmacies, so revenue is large relative to profit. Sinopharm, the state-owned national drug distributor, is its controlling shareholder.

In one line: A regional McKesson with a small factory arm.

Products and services

  • Pharmaceutical wholesale distribution
  • Retail pharmacy chain
  • Generic drug manufacturing

Customers

  • Hospitals
  • Retail pharmacies
  • Clinics

Where it sits in the supply chain

  • Pharmaceuticals
  • Distribution
  • Wholesale and retail pharmacy

What could go right

  • Hospital and pharmacy channel growth
  • Distribution consolidation in Guangdong

What could go wrong

  • Thin distribution margins
  • Drug pricing reform

Moat: narrow (scale, distribution). Dense South China distribution network under state-owned Sinopharm's national logistics umbrella.

Headquarters: Shenzhen, China · Employees: 28,336

Named competitors

China National Accord Medicines at a glance

Size China National Accord Medicines (000028.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.81B, the 1270th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥21.24 on 18 Nov 2026.

Performance Over six months the shares fell 3.2%, against -10.4% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 0.4% over the last twelve months (peer median +10.0%); the operating margin is 2.3% (peer median 14.4%).

Valuation It trades at 10.8× forward earnings against a peer median of 20.4× (2nd cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -14 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 1.4 points above its cost of capital (5.0% WACC).

Next results Next results expected around 14 Apr 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026000028.SZ 98Peer median 92
Six months, rebased to 100: China National Accord Medicines against the median of its 20 peers (local-currency closes).

China National Accord Medicines financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥73.4BCN¥73.3BCN¥74.3BCN¥75.4BCN¥73.3B
Revenue growth—-1%-1%+3%—
Gross profitCN¥7.68BCN¥6.36BCN¥6.46BCN¥7.40BCN¥7.38B
EBITDAn/aCN¥3.14BCN¥3.25BCN¥3.92BCN¥3.79B
Net incomeCN¥1.13BCN¥1.14BCN¥642MCN¥1.60BCN¥1.49B
Free cash flowCN¥1.50BCN¥1.52BCN¥3.18BCN¥2.85BCN¥2.21B
Capital expenditureCN¥139MCN¥217MCN¥283MCN¥322MCN¥322M
Total debtCN¥12.0BCN¥14.7BCN¥14.3BCN¥13.8BCN¥10.6B

Quarterly statements and history in the cockpit →

China National Accord Medicines competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%-10%0%+10%ZYMERARE3010150023996055073933300573ETON600664DMP000908AGIO600211300009ALIVUSNATCOPHARMSHILPAMED688166000028.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. China National Accord Medicines is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×150×ZYMERARE3010150023996055073933300573ETONCOHANCEPFIZERNATCOPHARMSHILPAMED688166000028.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. China National Accord Medicines is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%301015002399605507ETON688166000028.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. China National Accord Medicines is the large dot.

China National Accord Medicines competitors and peer comparison

Head to head with its named competitors (000028.SZ vs 3320.HK vs 601607.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
China National Accord Medicines 000028.SZ$1.81B-3%0%2%10.8×-9.5%
China Resources Pharmaceutical 3320.HK$3.60B-7%+8%4%5.8×-4.9%
Shanghai Pharmaceuticals 601607.SS$8.23B0%+4%3%11.2×-10.1%

How China National Accord Medicines compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China National Accord Medicines against its 20 peers (data as of 18 Nov 2026)
Measure000028.SZPeer medianRank in peer set
1-month return+5.5%+0.1%5th highest of 21
6-month return-3.2%-10.4%9th highest of 21
Distance from 52-week high-14.8%-32.8%3rd highest of 21
Revenue growth (TTM)+0.4%+10.0%6th lowest of 21
Operating margin2.3%14.4%5th lowest of 21
Forward P/E10.8×20.4×2nd cheapest of 19
Growth the price implies (Req g, 7 yrs)-9.5%6.7%least demanding of 15
Growth delivered (Del g)+4.2%+8.1%3rd lowest of 15
Hurdle (Req g minus delivered)-13.8 pp-3.9 pp4th least demanding of 15
ROIC minus cost of capital+1.4 pp+0.9 pp11th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%

Questions

Who are China National Accord Medicines's main competitors?
Named competitors: China Resources Pharmaceutical (3320.HK), Shanghai Pharmaceuticals (601607.SS). The cockpit's measured peer set (industry) also includes Zymeworks (ZYME), Ultragenyx Pharmaceutical (RARE), Qingdao Baheal Medical (301015.SZ), Shenzhen Hepalink Pharmaceutical (002399.SZ), Guobang Pharma (605507.SS), United Laboratories International (3933.HK).
Is China National Accord Medicines expensive compared with its peers?
On forward p/e it trades at 10.8× against a peer median of 20.4×, 2nd cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -14 pp: the price already allows for a slowdown.
How has China National Accord Medicines stock performed?
Over six months to 18 Nov 2026 the shares returned -3.2% against -10.4% for the median peer; over one year -7.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.